You're wrong this time.
But you've said it correctly on other occasions.
I guess a slip of the pen this time.
If the results were already clinically meaningful and statistically significant at the interim, the DSMB would have concluded "overwhelming efficacy" and recommended to switch the placebo patients onto the treatment. A "continue unchanged" decision would have been unethical.
(I think you owe @MongooseMan an apology).
Ann: Dimerix Successfully Passes Efficacy Interim Analysis, page-76
-
- There are more pages in this discussion • 204 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
52.5¢ |
Change
-0.005(0.94%) |
Mkt cap ! $288.8M | |||
| Open | High | Low | Value | Volume |
| 52.5¢ | 53.5¢ | 51.5¢ | $401.8K | 771.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 25424 | 52.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 53.0¢ | 221034 | 5 |
View Market Depth
| Last trade - 16.10pm 02/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |